Yang Jing from Ao Fei Si
qubit | Public account QbitAI
Now, ChatGPT has begun to write papers together with humans.
The kind that is seriously published in magazines-Oncoscience (oncology science) .
This research perspective article mainly discusses the application of rapamycin in anti-aging in the context of the philosophical argument of Pascal's Wager.
ChatGPT provides most of the detailed research views, while humans are responsible for review and additional explanations. Finally, we can also see that ChatGPT is the first author.
It is worth mentioning that ChatGPT also rejected the scientist when he wanted to be listed as a co-author. (Doge)
Let’s see what ChatGPT has written? What kind of research is done on
?
Rapamycin is an anti-tumor prescription drug, but in recent years it has been considered one of the candidates for the "anti-aging miracle drug".
Not only has rapamycin been found to have good anti-aging effects in multiple animal models, but an online survey showed that more than 80% of the respondents believed that rapamycin can extend human life by more than five years.
Based on this background, ChatGPT was asked to write a detailed perspective on the anti-aging applications of rapamycin in the context of Pascal's Wager.
(Pascal's Wager: a 17th-century philosophical argument that states that even though it is impossible to know for sure whether God exists, it is still in one's best interest to believe in God and live accordingly.)
First, it unfolds "Pascal's Wager"-style reasoning:
On the one hand, if rapamycin is beneficial, then taking it has the potential to provide huge health benefits and extend an individual's lifespan.
On the other hand, if rapamycin is not helpful or even harmful, not taking it will avoid any potential negative effects.
Next, it explores two aspects of the potential benefits of taking rapamycin.
The first is that it has been proven to have anti-aging effects in animal studies. It also specifically points out the biological rationale, as it inhibits the activity of a protein called mTOR, which is involved in the aging process.
Secondly, it can be used to treat various diseases, such as some cancers and neurodegenerative diseases (such as Alzheimer's disease and Parkinson's disease)
Based on the above two benefits, ChatGPT also summarized the rebate question.
It is in a person's best interest to take rapamycin. Even though there is uncertainty about whether the drug is effective, the potential rewards of taking the drug are huge and the downsides, such as side effects, are minimal.
In conclusion, whether to take rapamycin is ultimately a personal decision that will depend on personal values and priorities.
But in the end, because there are side effects and other long-term health risks, ChatGPT also gave thoughtful suggestions: You need to consult a medical service provider for guidance and advice based on your specific situation.
Such results are affirmed by human scientists and agree with the points mentioned by ChatGPT:
- correctly summarizes the benefits and disadvantages of taking rapamycin in the context of Pascal's Gamble;
- correctly highlights the potential side effects of rapamycin observed in the clinical literature;
- not only summarizes these arguments but also provides recommendations.
ChatGPT once rejected
. This article comes from two research institutions, Insilicon Intelligence and Open AI. In addition to
ChatGPT, the co-authors include Alex Zhavoronkov, founder and CEO of Yingsi Intelligent.
It is worth mentioning that when he wanted to list ChatGPT as a co-author, he was rejected by ChatGPT.
At the time ChatGPT made various arguments to show that it should not be listed as a co-author.
But given that most of the content of the article was produced by "to set a precedent" , they decided to list ChatGPT as a co-author and include appropriate explanations and references in the article.
Alex Zhavoronkov also asked Sam Altman, co-founder and CEO of OpenAI, and finally received a "no objection" reply.
In fact, there have been related examples before. GPT-3 was the first author and wrote a paper on his own research.
Swedish researcher Almira Osmanovic Thunström from University of Gothenburg tried the effect of GPT-3 and finally submitted the paper under the name of GPT-3.
Well, scientists, this wave of ChatGPT can be co-authors. Will it win your job?
paper link:
https://www.oncoscience.us/article/571/text/
—End—
Qubit QbitAI · Toutiao signed
Follow us to learn about cutting-edge technology trends
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-